June 24, 2019

Neil Kumar, Ph.D.
Chief Executive Officer
BridgeBio Pharma LLC
421 Kipling Street
Palo Alto, CA 94301

       Re: BridgeBio Pharma, Inc.
           Amendment No. 3 to Registration Statement on Form S-1
           Filed June 24, 2019
           File No. 333-231759

Dear Dr. Kumar:

       We have reviewed your amended registration statement and have the
following
comment. In our comment, we may ask you to provide us with information so we
may better
understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to the comment, we may have additional comments.

Amendment No. 3 to Form S-1 filed on June 24, 2019

Exhibits

1.     We note your disclosure on page 250 of your registration statement under
the heading
       "Description of Capital Stock" stating that the forum selection
provision in your amended
       and restated by-laws does not apply to any actions arising under the
Securities Act or
       Exchange Act. Please ensure that the exclusive forum provision in your
by-laws states this
       clearly, or tell us how you will inform investors in future filings that
the provision does
       not apply to any actions arising under the Securities Act or Exchange
Act.
 Neil Kumar, Ph.D.
BridgeBio Pharma LLC
June 24, 2019
Page 2

       You may contact Rolf Sundwall at 202-551-3105 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Christine Westbrook at 202-551-5019 or Erin Jaskot at 202-551-3442 with
any other
questions.



                                                        Sincerely,
FirstName LastNameNeil Kumar, Ph.D.
                                                        Division of Corporation
Finance
Comapany NameBridgeBio Pharma LLC
                                                        Office of Healthcare &
Insurance
June 24, 2019 Page 2
cc:       Maggie Wong, Esq.
FirstName LastName